ClinicalTrials.gg
CompletedNCT06853132Updated Oct 23, 2026

Baduanjin With Resistance Training Program

An interventional study of Baduanjin with Resistance Training Program in Osteoporosis and Lumbar Disc Herniation, sponsored by Yale University. Completed at 1 site in China. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Yale University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 23, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Enrollment
26th of 57
136 · median 120
Started
2025
with 10 others
No phase
19 of 87
5 open now
Registered
68th of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 26th largest by enrollment of the 57 interventional ones that give a count, is one of 11 that started in 2025, is one of 19 with no phase, and was the 68th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to improve symptoms of Lumbar Disc Herniation (LDH) and Osteoporosis (OP) by implementing an evidence-based Baduanjin exercise to reduce pain and increase muscle strength and quality of life in Chinese patients. This study will provide new sights of exercise of elderly patients with LDH and OP for elderly patients.

Read the detailed description

Participants in the control group will continue with their conventional post surgery treatment as follows: comprehensive post-operative care and educational handouts that include guidelines for lumbar and back exercises to improve recovery and promote spinal health. In addition, participants will receive three interactive Q\&A sessions before discharge (pre-operation, post-operation, and on the day of discharge). During these sessions, patients can discuss their concerns and ask questions about their recovery.

Participants in the experimental group will continue to receive their conventional post surgery treatment in addition to BDJ as follows: Individual session training (admission to week 1 post-surgery), no training week 2, Group session I (week 3 and 4), Group session 2 (week 5-12) and perform independent exercises during which participants will have to keep an exercise diary (week 13-24).

Data collection will be conducted through in-person visits at baseline and Week 1, followed by phone calls at Week 12 and Week 24.

03

Conditions studied

  • Osteoporosis
  • Lumbar Disc Herniation
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with LDH and OP based on the chart and clinical diagnostic criteria.
  • Age of female patients ≥ 45 years,age of male patients ≥ 50 years.
  • Visual analogue scale (VAS) ≥ 3 points.
  • Surgical operation will be performed during the 7-day admission period.
  • Mandarin speakers.

Exclusion criteria

Exclusion Criteria:

  • Severe primary diseases: ulcerative colitis, gastrointestinal bleeding, pancreatitis, lung cancer, pneumonia, acute respiratory distress syndrome or psychosis, depression, anxiety or substance abuse, identified by diagnosis and interview.
  • Current engagement in regular physical activity routines over the past 3 months: aerobic exercises for at least 30 minutes, at least 3 times per week.
  • Taken drugs within 3 months before enrollment: bisphosphonates, , calcitonin, anticonvulsant drugs, heparin, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • No intervention
    Control Group

    Participants will receive conventional (usual) treatment: continue with their original treatment, medication, and diet habits. After spinal surgery, two nurses trained according to this study protocol will teach participants standard guidance for lumbar and back exercises, which will include exercise suggestions and health education.

  • Experimental
    BDJ with resistance training

    BDJ exercise combined with resistance training and conventional (usual) treatment in the experimental group. Two nurses will provide training to ensure that participants can perform the movements skillfully and coherently.

    Behavioral: Baduanjin with Resistance Training Program

Interventions

  • BehavioralBaduanjin with Resistance Training Program

    Baduanjin with Resistance Training Program

06

What researchers measure

Primary outcomes

  1. Change in Quality of life measured by the Oswestry Disability Index (ODI)

    ODI is the most widely accepted scales for assessing quality of life and the severity of disability caused by back pain. It assesses the impact of back pain on various daily activities. The ODI is a questionnaire containing 10 items covering disability caused by low back pain. Each item is assessed on a six-level ordinal scale with "0" describing "no limitation" and "5" describing "extreme limitation or an inability to function", with higher values representing a greater extent of disability. The total score is converted to a percentage to determine the severity of disability. Scores are interpreted as follows: 0-20% (minimal disability), 21-40% (moderate disability), 41-60% (severe disability), 61-80% (crippled), and 81-100% (bed-bound or exaggerating symptoms). The Cronbach's alpha of this scale was 0.89.

    Time frame: Weeks 0, 1, 12, and 24

  2. Change in Muscle strength by the Five Times Sit-to-Stand Test (FTSS)

    The researchers need to record the total time spent going from sit to stand. At last, the test will be performed three times, and the final average in seconds is taken. Each patient was given 2 minutes intervals for rest. The time it takes to complete the five times sit-to-stand test (FTSST) varies by age and gender. Healthy adults complete the test in ≤ 10 seconds; times ≥15 seconds indicate increased fall risk and mobility impairments. The Cronbach alpha 0.99, and the reliability was 0.97.

    Time frame: Weeks 0, 1, 12, and 24

  3. Change in physical activity level by the International Physical Activity Questionnaire (IPAQ).

    The IPAQ-LC is a widely used tool for assessing physical activity levels in various populations. This scale requires participants to complete 31 questions across four activity domains (transportation, work, household, and leisure time), and includes sections on walking, moderate and vigorous activity, and sedentary behaviors (sitting and lying awake\]. The exercises recorded must last at least 10 minutes each time. To calculate a total activity score, the reported activity is assigned a Metabolic Equivalents (MET) value based on its intensity. (1) Low Activity Level: \<600 MET minutes/ a week; (2) Moderate Activity Level: 600\~3000 MET minutes/ a week; (3) \> 3000 MET minutes/ a week. The Cronbach's alpha of this scale was 0.88.

    Time frame: Weeks 0, 1, 12, and 24

Secondary outcomes

  1. Change in Exercise self-efficacy by the Self-Efficacy for Exercise Scale (SEE)

    This scale is designed to test individual's confidence to exercise in the face of barriers to exercise. It consists of 9 items, with scores ranging from 0 to 10 representing the exercise confidence levels. A score of 0 indicates "no confidence", while a score of 10 indicates "very confident". Total score range is 0-90. Higher scores reflect a greater level of exercise self-efficacy. The Cronbach alpha for this scale is 0.93.

    Time frame: Weeks 0, 1, 12, and 24

  2. Change in exercise benefit by the Exercise Benefits and Barriers Scale (EBBS)

    This scale assesses the perceived benefits and barriers to exercise among patients. The EBBS consists of 43 items that evaluate the perceived benefits of exercise and factors that hinder participation. It includes two dimensions: exercise benefits and exercise barriers. A 4-point Likert scale is used (1 = "strongly disagree", 4 = "strongly agree"). The total score ranges from 43 to 172, with higher scores indicating more positive perceptions of exercise benefits and fewer perceived barriers. The Cronbach alphas for the overall scale and the two subscales are 0.86, 0.95, and 0.86, respectively.

    Time frame: Weeks 0, 1, 12, and 24

  3. Incidence of complications after surgery

    Complications will be recorded by registered nurses. The data will be collected by clinical chart reviews and patient interviews. The incidence of complication after surgery will be calculated by the number of new complications / total number of participants in each group.

    Time frame: Week 1

07

Study locations

1 site
  • Second Xiangya Hospital
    Changsha, Hunan, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jun 2026, 9 months.

Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's 9 months is below that.

Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 28, 2025
StartActual
Aug 30, 2025
Primary completionActual
Jun 5, 2026
CompletionActual
Aug 10, 2026was Jun 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Primary completion
Jun 30, 2026→Jun 5, 2026 (actual)
Oct 23, 2026
Study completion
Jun 30, 2026→Aug 10, 2026 (actual)
Oct 23, 2026
Enrollment
110 (estimated)→136 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2026→Jun 5, 2026 (now actual)
    Study completion Jun 30, 2026→Aug 10, 2026 (now actual)
    Enrollment 110 (estimated)→136 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06853132
Lead sponsor
Yale University
Collaborators
Yale-China Association
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Aug 30, 2025
Primary completion
Jun 5, 2026
Completion
Aug 10, 2026
Last update
Oct 23, 2026

Study contacts

Soohyun Nam, PhD, APRN, ANP-BC, FAHA, FAAN
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion